← Evidence library

BIB_334

Schumann J, Dummer R et al. (Zurich + multicentre). Switching PD-1 to BRAF + MEK inhibition in second-course adjuvant melanoma therapy. J Eur Acad Dermatol Venereol 2025. PMID/DOI 10.1111/jdv.20708. Key finding: in patients receiving second course of adjuvant therapy, switching from PD-1 → BRAF/MEK gives better RFS than the reverse switch. [Tasks: 17, 18, 19b] Tier: 2 (retrospective real-world) Grade: B Retrieved: 2026-05-15

Evidence grade

B

Tier

2 (retrospective real-world)

Cited by tasks

17, 18, 19b

Identifiers

DOI:10.1111/jdv

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_334/findings.md (research corpus). This page is a short context summary — not individualised medical advice.